請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49638
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李心予(Hsinyu Lee) | |
dc.contributor.author | Jui-Chung Chiang | en |
dc.contributor.author | 江瑞中 | zh_TW |
dc.date.accessioned | 2021-06-15T11:39:08Z | - |
dc.date.available | 2021-10-05 | |
dc.date.copyright | 2016-10-05 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-15 | |
dc.identifier.citation | 1. Orkin, S.H. and L.I. Zon, Hematopoiesis: an evolving paradigm for stem cell biology. Cell, 2008. 132(4): p. 631-44.
2. Jagannathan-Bogdan, M. and L.I. Zon, Hematopoiesis. Development, 2013. 140(12): p. 2463-7. 3. Galloway, J.L. and L.I. Zon, Ontogeny of Hematopoiesis: Examining the Emergence of Hematopoietic Cells in the Vertebrate Embryo. Developmental Biology, 2003. 53: p. 139-58. 4. Palis, J. and M.C. Yoder, Yolk-sac hematopoiesis: The first blood cells of mouse and man. Experimental Hematology, 2001. 20(8): p. 927-36. 5. Inman, K.E. and K.M. Downs, The murine allantois: emerging paradigms in development of the mammalian umbilical cord and its relation to the fetus. Genesis, 2007. 45(5): p. 237-58. 6. Zon, L.I., Developmental Biology of Hematopoiesis. Blood, 1995. 86(8): p. 2876-91. 7. Till, J.E. and E.A. McCulloch, Hemopoietic stem cell differentiation. Biochimica et Biophysica Acta, 1980. 605(4): p. 431-59. 8. Spangrude, G.J., et al., Mouse Hematopoietic Stem Cells. Blood, 1991. 78(6): p. 1395-402. 9. Ivanovs, A., et al., Highly potent human hematopoietic stem cells first emerge in the intraembryonic aorta-gonad-mesonephros region. J Exp Med, 2011. 208(12): p. 2417-27. 10. Muller, A.M., et al., Development of Hematopoietic in the Mouse Embryo. Immunity, 1994. 1: p. 291-301. 11. Cumano, A. and I. Godin, Ontogeny of the hematopoietic system. Annu Rev Immunol, 2007. 25: p. 745-85. 12. Wolber, F.M., et al., Roles of spleen and liver in development of the murine hematopoietic system. Exp Hematol, 2002. 30(9): p. 1010-9. 13. Notta, F., et al., Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science, 2016. 351(6269): p. aab2116. 14. Seita, J. and I.L. Weissman, Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med, 2010. 2(6): p. 640-53. 15. Morrison, S.J.W., I. L., The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity, 1994. 1: p. 661-73. 16. Christensen, J.L. and I.L. Weissman, Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A, 2001. 98(25): p. 14541-6. 17. Kondo, M., I.L. Weissman, and K. Akashi, Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow. Cell, 1997. 91(5): p. 661-72. 18. Serwold, T., L.I. Ehrlich, and I.L. Weissman, Reductive isolation from bone marrow and blood implicates common lymphoid progenitors as the major source of thymopoiesis. Blood, 2009. 113(4): p. 807-15. 19. Akashi, K., et al., A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature, 2000. 404(6774): p. 193-7. 20. Klimchenko, O., et al., A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood, 2009. 114(8): p. 1506-17. 21. Pardanaud, L. and F. Dieterlen-Lievre, Manipulation of the angiopoietic/hemangiopoietic commitment in the avian embryo. Development, 1999. 126: p. 617-27. 22. Reya, T., et al., A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 2003. 423. 23. Cobas, M., et al., Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med, 2004. 199(2): p. 221-9. 24. Duncan, A.W., et al., Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol, 2005. 6(3): p. 314-22. 25. Calvi, L.M., et al., Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 2003. 425: p. 841-6. 26. Kiel, M.J. and S.J. Morrison, Maintaining hematopoietic stem cells in the vascular niche. Immunity, 2006. 25(6): p. 862-4. 27. Kiel, M.J., G.L. Radice, and S.J. Morrison, Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell, 2007. 1(2): p. 204-17. 28. Akkerman, J.W., Thrombopoietin and platelet function. Semin Thromb Hemost, 2006. 32(3): p. 295-304. 29. Vigon, I., et al., Molecular cloning and characterization ofMPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci, 1992. 89(15): p. 5640-4. 30. Witthuhn, B.A., et al., JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 1993. 74: p. 227-36. 31. Tortolani, P.J., et al., Thrombopoietin Induces Tyrosine Phosphorylation and Activation of the Janus Kinase, JAK2. Blood, 1995. 85(12): p. 3444-51. 32. Burns, C.E., et al., Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev, 2005. 19(19): p. 2331-42. 33. Krivtsov, A.V., et al., Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature, 2006. 442(7104): p. 818-22. 34. Kim, S.I. and E.H. Bresnick, Transcriptional control of erythropoiesis: emerging mechanisms and principles. Oncogene, 2007. 26(47): p. 6777-94. 35. Saleque, S., et al., Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell, 2007. 27(4): p. 562-72. 36. Galloway, J.L., et al., Loss of gata1 but not gata2 converts erythropoiesis to myelopoiesis in zebrafish embryos. Dev Cell, 2005. 8(1): p. 109-16. 37. Rhodes, J., et al., Interplay of pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. Dev Cell, 2005. 8(1): p. 97-108. 38. Usui, T., et al., T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med, 2006. 203(3): p. 755-66. 39. Iwasaki, H., et al., GATA-1 Converts Lymphoid and Myelomonocytic Progenitors into the Megakaryocyte/Erythrocyte Lineages. Immunity, 2003. 19(3): p. 451-62. 40. Frontelo, P., et al., Novel role for EKLF in megakaryocyte lineage commitment. Blood, 2007. 110(12): p. 3871-80. 41. Starck, J., et al., Functional Cross-Antagonism between Transcription Factors FLI-1 and EKLF. Molecular and Cellular Biology, 2003. 23(4): p. 1390-1402. 42. Aoki, J., Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol, 2004. 15(5): p. 477-89. 43. Tokumura, A., et al., Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem, 2002. 277(42): p. 39436-42. 44. Umezu-Goto, M., et al., Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol, 2002. 158(2): p. 227-33. 45. Yanagida, K., et al., Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem, 2009. 284(26): p. 17731-41. 46. Choi, J.W., et al., LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol, 2010. 50: p. 157-86. 47. Bandoh, K., et al., Lysophosphatidic acid (LPA) receptors of the EDG family are di!erentially activated by LPA species. FEBS Letters, 2000. 478. 48. Moolenaar, W.H., LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol., 1994. 4(6): p. 213-9. 49. Chiang, C.L., et al., Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3. Stem Cells, 2011. 29(11): p. 1763-73. 50. Ho, Y.H., et al., Opposing regulation of megakaryopoiesis by LPA receptors 2 and 3 in K562 human erythroleukemia cells. Biochim Biophys Acta, 2015. 1851(2): p. 172-83. 51. Lin, K.H., et al., Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesis. Sci Rep, 2016. 6: p. 27050. 52. Li, H., et al., Lysophosphatidic acid acts as a nutrient-derived developmental cue to regulate early hematopoiesis. EMBO J, 2014. 33(12): p. 1383-96. 53. Igarashi, H., et al., The lysophosphatidic acid receptor LPA4 regulates hematopoiesis-supporting activity of bone marrow stromal cells. Sci Rep, 2015. 5: p. 11410. 54. Evseenko, D., et al., Lysophosphatidic acid mediates myeloid differentiation within the human bone marrow microenvironment. PLoS One, 2013. 8(5): p. e63718. 55. Carraway, M.S., et al., Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. Circ Res, 2010. 106(11): p. 1722-30. 56. Aisen, P., Transferrin receptor 1. Int J Biochem Cell Biol, 2004. 36(11): p. 2137-43. 57. Marsee, D.K., G.S. Pinkus, and H. Yu, CD71 (transferrin receptor): an effective marker for erythroid precursors in bone marrow biopsy specimens. Am J Clin Pathol, 2010. 134(3): p. 429-35. 58. Spangrude, G.J., S. Heimfeld, and I.L. Weissman, Purification and characterization of mouse hematopoietic stem cells. SCIENCE, 1988. 241: p. 58-62. 59. Osawa, M., K. Hanada, and H.N. Hamada, H., Long-term lymphohematopoietic reconstitution by a single CD34± low/negative hematopoietic stem cell. SCIENCE, 1996. 273: p. 242-5. 60. Koulnis, M., et al., Identification and analysis of mouse erythroid progenitors using the CD71/TER119 flow-cytometric assay. J Vis Exp, 2011(54). 61. Sackey, K., Hemolytic Anemia: Part 1. Pediatr Rev, 1999. 5: p. 152-8. 62. Berger, J., Phenylhydrazine haematotoxicity. J. Appl. Biomed., 2007. 5: p. 125-30. 63. Lee, H.Y., et al., PPAR-alpha and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal. Nature, 2015. 522(7557): p. 474-7. 64. Kanstrup, I.L. and B. Ekblom, Blood volume and hemoglobin concentration as determinants of maximal aerobic power. Medicine & Science in Sports & Exercise, 1984. 16(3): p. 256-62. 65. Ekblom, B. and R. Huot, Response to submaximal and maximal exercise at different levels of carboxyhemoglobin. Acta Physiol Scand., 1972. 86(4): p. 474-82. 66. Calbet, J.A., et al., Importance of hemoglobin concentration to exercise: acute manipulations. Respir Physiol Neurobiol, 2006. 151(2-3): p. 132-40. 67. Steevels, T.A., et al., Co-expression of the collagen receptors leukocyte-associated immunoglobulin-like receptor-1 and glycoprotein VI on a subset of megakaryoblasts. Haematologica, 2010. 95(12): p. 2005-12. 68. Kim, H.O., In-vitro stem cell derived red blood cells for transfusion: are we there yet? Yonsei Med J, 2014. 55(2): p. 304-9. 69. Zimmet, J. and K. Ravid, Polyploidy: Occurrence in nature, mechanisms, and significance for the megakaryocyte-platelet system. Exp. Hematol, 2000. 28: p. 3-16. 70. Machlus, K.R. and J.E. Italiano, Jr., The incredible journey: From megakaryocyte development to platelet formation. J Cell Biol, 2013. 201(6): p. 785-96. 71. Tsai, F.Y. and S.H. Orkin, Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood, 1997. 89: p. 3636-43. 72. Love, P.E., C. Warzecha, and L. Li, Ldb1 complexes: the new master regulators of erythroid gene transcription. Trends Genet, 2014. 30(1): p. 1-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49638 | - |
dc.description.abstract | 造血作用 (Hematopoiesis) 為一連續性的發育過程,其產生各類生物體所需之血球細胞,以維持血液系統恆定,其中骨髓系統 (Myeloid lineage) 為一重要分支,而在本實驗室過去研究指出,水解磷酸脂 (lysophosphatidic acid, LPA) 藉由活化特定受器參與調控骨髓系統中紅血球與巨核細胞的分化,因此,本篇研究透過小鼠動物模式,進一步探討LPA在哺乳動物骨髓系統中所扮演之角色。首先,透過分析LPA2和LPA3在骨髓系統中各個時期前驅細胞上的表現量,發現此兩種受器分別表現於血球分化過程中的不同時期,接著我們進一步給予此兩種受器之增效劑,GRI用以針對LPA2,而OMPT則為LPA3,並分別分析骨髓和脾臟等造血組織中各種血球前驅細胞,以及周邊血液中成熟血球細胞,實驗結果顯示,LPA2作用於上游前驅細胞,並抑制整體下游骨髓系統,使紅血球與巨核細胞的分化皆受到抑制,而LPA3則作用在較晚期的前驅細胞,促進紅血球生成,反之抑制巨核細胞的分化路徑,而這樣的分化能力則可望應用於貧血治療上,因此我們最後在苯胼 (Phenylhydrazine, PHZ) 所誘發的貧血小鼠模式中發現,OMPT對比對照組,其貧血之病徵受到減緩。本研究中所發現LPA2和LPA3兩受器在血球分化中所扮演的調控角色,可作為研究水解磷酸脂及哺乳動物骨髓系統關係之指標,並可望作為貧血治療的新興藥物。 | zh_TW |
dc.description.abstract | Hematopoiesis is the process to form blood components and replenish the blood system, including myeloid cell differentiation which is one of the most crucial physiological processes. Our previous studies demonstrated that lysophosphatidic acid (LPA), through activating G-protein-coupled receptors of LPA1-6, regulates myeloid cell differentiation. However, the underlie mechanisms in vivo remain unclear. In this study, we aimed to validate the effects of LPA and its corresponding receptors, LPA2 and LPA3 on erythropoiesis/megakaryopoiesis. Analyzing LPA receptors profile of mice myeloid cells, we observed that LPA2 and LPA3 express at different stages of progenitors. Mice injected with LPA2 agonist, GRI977143, showed decrease in both erythroid and megakaryocytic lineages. GRI treatment was further found to suppress common myeloid progenitor (CMP) and megakaryocyte erythrocyte progenitor (MEP) populations, suggesting that LPA2 dominantly inhibits myeloid differentiation at the early stage of myelopoiesis. In contrast, treatment with LPA3 agonist, 1-oleoyl-2-O-methyl-rac-glycerophosphothionate (OMPT), seems to induce erythropoiesis at the expense of megakaryopoiesis, as evidenced by increase in erythroid populations and RBC numbers but decreased megakaryocyte populations. Moreover, the mRNA expression levels of myeloid specific transcription factors were altered in response to GRI and OMPT, suggesting that LPA2 and LPA3 exert opposing effects on myeloid transcriptional regulations. Finally, OMPT injection successfully restored PHZ-induced acute haemolytic anaemia. Taken together, this study demonstrated for the first time that LPA2 and LPA3 differently regulate hematopoiesis in vivo, and provide a potential therapeutic strategy for the treatment of anemia. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:39:08Z (GMT). No. of bitstreams: 1 ntu-105-R03b21023-1.pdf: 5240889 bytes, checksum: 9069c63c30c2d0eb7611c3f5022561ee (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 論文口試委員審定書…………………………………………………………………………i
致謝………………………………………………………………………ii 中文摘要…………………………………………………………………iv Abstract …………………………………………………………………v Contents………………………………………………………………vii Introduction……………………………………………………………1 Overview of vertebrate hematopoiesis……………………………1 Hematopoietic Regulators……………………………………………2 Lysophosphatidic acid (LPA)…………………………………………4 LPA and hematopoiesis…………………………………………………4 Rationale…………………………………………………………………6 Materials and Methods…………………………………………………7 Cell culture and pharmacological treatment……………………7 Mice and pharmacological treatment………………………………7 Haemolytic anaemia mice experiment………………………………8 Peripheral Blood Analysis …………………………………………8 Voluntary Exercise……………………………………………………9 Flow cytometric analysis and sorting ……………………………9 Immunofluorescence analysis ………………………………………10 RNA extraction and quantitative real-time PCR………………10 Statistical analysis…………………………………………………11 Results…………………………………………………………………12 LPA2 and LPA3 express at different stages of myeloid progenitors……………………………………………………………12 LPA2 agonist inhibits erythro-megakaryotic differentiation………………………………………………………14 LPA3 agonist promotes erythropoiesis at the expense of megakaryopoiesis………………………………………………………15 LPA2 and LPA3 have distinct regulatory functions in myelopoiesis……………………………………………………………17 LPA receptors regulate erythroid transcription factors…………………………………………………………………18 OMPT alleviates PHZ-induced hemolytic anemia……………………………………………………………………19 Discussion………………………………………………………………21 References………………………………………………………………26 Tables & Figures………………………………………………………34 Table 1. Real-time PCR primers (mice)…………………………34 Table 2. The general and hematology parameters of mice with 60 mg/kg PHZ administration ………………………………………35 Fig. 1 Pharmacological activation of LPA2 and LPA3 has opposite effects on erythroid differentiation………………36 Fig.2 LPA2 and LPA3 express on different stages of hematopoietic progenitor……………………………………………37 Fig.3 Pharmacological activation of LPA2 inhibits erythropoiesis…………………………………………………………39 Fig.4 Pharmacological activation of LPA2 reduces generation of megakaryocyte………………………………………………………42 Fig.5 Pharmacological activation of LPA3 increases erythropoiesis…………………………………………………………44 Fig.6 Pharmacological activation of LPA3 inhibits megakaryopoiesis………………………………………………………47 Fig.7 LPA2 and LPA3 act at different stages of hematopoietic progenitor……………………………………………49 Fig.8 Gene expression analysis in treatment mice by quantitative PCR………………………………………………………50 Fig.9 LPA3 agonist, OMPT alleviates the symptoms of hemolytic anemia ……………………………………………………52 Fig.10 LPA3 agonist, OMPT alleviates the athletic ability defect caused by hemolytic anemia ………………………………54 Fig.11 Model: LPA2 and LPA3 regulate erythro-megakaryocytic differentiation in myeloid lineage………………………………56 Supplemental Figures…………………………………………………57 Fig. S1 Distribution of myeloid progenitors in hematopoietic organs…………………………………………………57 Fig. S2 The mRNA expression level of LPA2 and LPA3 in series of hematopoietic progenitors at different stages…58 | |
dc.language.iso | en | |
dc.title | 水解磷酸酯受器增效劑調控哺乳動物骨髓系統中紅血球及巨核細胞分化之研究 | zh_TW |
dc.title | Pharmacological activation of LPA receptors regulates mammalian erythro-megakaryocytic differentiation in myeloid lineage | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 姚少凌,黃元勵,蔡素宜 | |
dc.subject.keyword | 造血作用,水解磷酸脂,骨髓系統,紅血球,巨核細胞,貧血, | zh_TW |
dc.subject.keyword | Hematopoiesis,Lysophosphatidic acid,Myeloid lineage,Erythrocyte,Megakaryocyte,Anemia, | en |
dc.relation.page | 58 | |
dc.identifier.doi | 10.6342/NTU201602444 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-16 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 5.12 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。